CRISCuris, Inc.Signing up patients
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Chronic Lymphocytic Leukemia · B-cell Malignancies
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 108 (planned)
- Started
- Apr 23, 2026
- Main results expected
- Nov 2027
- Fully finished
- Nov 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Undetectable Measurable Residual Disease (uMRD) Rate
Measured over: Up to approximately 23 months
Cohort 2: Overall Response Rate (ORR)
Measured over: Up to approximately 23 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07271667 · record last updated 2026-06-12 · checked 2026-11-09 15:47 UTC